UK testing Netflix-style payments to boost antibiotics development

Officials hope the model will overcome some of the obstacles that have stifled the commercial prospects for new antibiotics.

By Jacob Bell • July 9, 2019

BioMarin confirms timeline for hemophilia gene therapy, putting pressure on rivals

The biotech plans on submitting valrox to U.S. and European regulators in the fourth quarter, which could bring approval decisions by mid-2020.

By Jacob Bell • July 8, 2019

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Zolgensma set a new drug pricing bar. Insurers show some signs of pushback

One month after approval, a handful of payers have adopted policies taking a more cautious stance than what the FDA set out in the gene therapy's label.

By Ned Pagliarulo • Updated July 5, 2019

BioPharma Dive's 10 biggest stories of the spring

Developments in gene therapy, cancer treatments, drug pricing and dealmaking kept the industry in the headlines.

By Jacob Bell • July 3, 2019

Amarin to double sales team again as it boosts Vascepa sales forecast

The drugmaker also plans to start direct-to-consumer advertising in the second quarter of next year, aiming to further grow sales of the fish oil pill.

By Andrew Dunn • July 2, 2019

A spotlight on patient-provider dialogue

Patient-provider dialogue is a critical part of your brand’s success. Start giving it the attention it deserves.

July 2, 2019

Aiming for price transparency, Civica Rx hits snag with bundled payments

The payment model, often opaque on specific drug costs, affects many of the medicines the hospital-led group is targeting, according to its commercial chief.

By Jacob Bell • June 27, 2019

CMS approves Louisiana's 'Netflix model' using Gilead hepatitis C drugs

The subscription model will go into effect Monday, and a similar plan by Washington state is also expected to start next week.

By Rebecca Pifer • June 26, 2019

Samsung Bioepis CEO urges patience as US biosimilar market lags

"Market shaping takes time," the head of the Korean drugmaker told BioPharma Dive, as a few experts call to give up on the copycat biologics altogether. 

By Ned Pagliarulo • June 26, 2019

Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?

Gene therapies and other long-acting treatments are threatening to outdate the drugs Sanofi got from its Bioverativ deal.

By Jacob Bell • June 19, 2019

Upadacitinib a plus for AbbVie in rheumatoid arthritis, doc survey says

A Piper Jaffray survey of physicians suggests the new drug won't cannibalize Humira, but instead take market share from Olumiant and Xeljanz.

By Jonathan Gardner • June 14, 2019

Allergan reportedly hires Spark Foundry as US advertising agency

The new media agency will come on board as Allergan attempts to mount a turnaround, facing discontent from investors.

By Kristin Jensen • June 12, 2019

Influential task force urges payers to cover PrEP for HIV

The recommendation from the U.S. Preventive Services Task Force could expand access to Gilead's Truvada, which has come under scrutiny for its cost. 

By Samantha Liss • June 12, 2019

How pharma can drive value and embrace change in an evolving marketplace

Pharma sales organizations need to adapt to today's evolving healthcare marketplace.

June 11, 2019

Novo Nordisk goes for broke on semaglutide heart data

The diabetes giant is asking the FDA for permission to market cardiovascular claims before a long-term outcomes study is complete.

By Jonathan Gardner • June 11, 2019

Judge, CVS witness clash on merger settlement, July hearing set

Federal Judge Richard Leon told lawyers they might want to cancel their summer vacation plans as he voiced concern about the leverage the merged health giant will wield in the marketplace.

By Dana Elfin • June 6, 2019

Mitsubishi pulls EU application for ALS drug, citing 'unwarranted' data request

Regulators had concerns that data from a key study that has helped Radicava in other markets isn't strong enough to warrant approval in the bloc.

By Jacob Bell • May 31, 2019

Seniors' out-of-pocket spending on cancer drugs climbs higher

Despite efforts to limit Medicare Part D beneficiaries' financial exposure to high-cost drugs, price increases have wiped out some of the expected savings.

By Samantha Liss • May 29, 2019

Gilead C-suite shifts again with chief commercial officer appointment

Bristol-Myers Squibb veteran Johanna Mercier will fill the position in July, while Laura Hamill, who joined Gilead's top ranks last year, will be leaving.

By Jacob Bell • May 29, 2019

Teva settles for $85M in Oklahoma opioid lawsuit

Yet a looming question for the Israeli pharmaceutical giant, as well as other drugmakers, is whether more states will follow in suing over the opioid crisis.

By Jacob Bell • May 28, 2019

Novartis gene therapy approved, but will come at cost of more than $2M

Zolgensma is designed to be a cure for spinal muscular atrophy, but its steep price will pose difficulties for a system designed for chronic therapy rather than one-time treatments. 

By Ned Pagliarulo • Updated May 24, 2019

ICER sees current DMD therapies as too pricey, but notes data limitations

Though evidence supporting Sarepta's eteplirsen and golodirsen and PTC's deflazacort "remains sparse," ICER expects all three drugs wouldn't hit certain cost-effectiveness thresholds.

By Jacob Bell • May 23, 2019

Private payers cover more than 40% of drug costs

Patients pay 14% of overall retail drug spend in the U.S. in the form of out-of-pocket costs, according to a new analysis from the Kaiser Family Foundation.

By Rebecca Pifer • May 21, 2019

ICER seeks to make drug price research more accessible

Pharmas and payers use ICER's work to inform their approach on pricing and coverage, making the group a key voice in the debate over drug value.

By Ned Pagliarulo • May 20, 2019

The NASH dash runs into some early hurdles

In a trio of articles, BioPharma Dive explored the key problems the NASH field faces and what's being done to solve them.

By Jacob Bell • May 17, 2019